TORONTO - A clinical trial has found that a simple drug regimen delivered over 12 weeks achieved sustained eradication of several strains of hepatitis C in 99 per cent of patients treated with the medications, researchers reported Monday.
Their study, published in the New England Journal of Medicine, showed that receiving a once-daily combination of sofosbuvir-velpatasvir for a 12-week period was effective in both previously treated and never-treated patients with hepatitis C genotypes 1, 2, 4, 5 or 6.
"This drug regimen changes the standard of care in treating patients with HCV. We can now cure almost everyone with a very simple treatment," said lead researcher Dr. Jordan Feld, a liver specialist at Toronto Western Hospital.
Labels: 2, 4, 5, 6, Genotype 1, HCV drug pipeline, sofosbuvir plus velpatasvir